Send to

Choose Destination
Chembiochem. 2019 Apr 23. doi: 10.1002/cbic.201900158. [Epub ahead of print]

Biocatalytic Reversal of Advanced Glycation End Product Modification.

Author information

Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT, 06511, USA.
Chemical Biology Institute, Yale University, 600 West Campus Drive, West Haven, CT, 06516, USA.
Department of Pharmacology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Department of Microbial Pathogenesis, Yale School of Medicine, 295 Congress Avenue, New Haven, CT, 06536, USA.


Advanced glycation end products (AGEs) are a heterogeneous group of molecules that emerge from the condensation of sugars and proteins through the Maillard reaction. Despite a significant number of studies showing strong associations between AGEs and the pathologies of aging-related illnesses, it has been a challenge to establish AGEs as causal agents primarily due to the lack of tools in reversing AGE modifications at the molecular level. Herein, we show that MnmC, an enzyme involved in a bacterial tRNA-modification pathway, is capable of reversing the AGEs carboxyethyl-lysine (CEL) and carboxymethyl-lysine (CML) back to their native lysine structure. Combining structural homology analysis, site-directed mutagenesis, and protein domain dissection studies, we generated a variant of MnmC with improved catalytic properties against CEL in its free amino acid form. We show that this enzyme variant is also active on a CEL-modified peptidomimetic and an AGE-containing peptide that has been established as an authentic ligand of the receptor for AGEs (RAGE). Our data demonstrate that MnmC variants are promising lead catalysts toward the development of AGE-reversal tools and a better understanding of AGE biology.


enzyme catalysis; glycation; oxidoreductases; protein engineering; protein modifications


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center